Acta Med. 2008, 51: 101-105
https://doi.org/10.14712/18059694.2017.10
Ionizing Radiation Sensitizes Leukemic MOLT-4 Cells to TRAIL-induced Apoptosis
References
1. C, Schmith B, Marini P, Durand E, Rudner J, Faltin HM, Bamberg M, Schutze-Osthoff K, Budach W. Sensitization of resistant lymphoma cells to irradiation/ induced apoptosis by the death ligand TRAIL. Oncogene 2001; 20:2190–6.
<https://doi.org/10.1038/sj.onc.1204318>
2. O, Subrata R, Bucur MC, Almasan A. APO2 ligand-tumor necrosis factorrelated apoptosis-inducing ligand in prostate cancer therapy. Frontiers in Bioscience 2006; 11:1549–68.
<https://doi.org/10.2741/1903>
3. GV, Li Y, Humphreys R, Andreeff M, O Brien S, Younes M. Activity od selective fully human agonistic antibodies to the TRAIL death receptors TRAIL- R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction apoptosis and enhancement of doxorubicin – and bortezomib-induced cell death. Br J Haematol 2005; 130:501–10.
<https://doi.org/10.1111/j.1365-2141.2005.05656.x>
4. B, Almasan A. Apo2 ligand=TNF-related apoptosis-inducing ligand and death receptor 5 mediate the apoptotic signaling induced by ionizing radiation in leukemic cells. Cancer Res. 2000; 60:5754–60.
5. ES, Johnston JB, Gibson SB. The role of TRAIL death receptors in the treatment of hematological malignancies. Leukemia and Lymphoma 2008; 49:27–35.
<https://doi.org/10.1080/10428190701713655>
6. AM, Huang Y, Fang G, Bhalla K. Over expression of Bcl-2 or Bcl-XL inhibits Ara-C-induced CPP32/Yama protease activity and apoptosis of human AML HL-60 cells. Cancer Res 1996; 56:4743–8.
7. SH, Steensma DP. On the TRAIL of a new therapy for leukemia. Leukemia 2005; 19:2195–202.
<https://doi.org/10.1038/sj.leu.2403946>
8. K, Fisher MJ, Xu SQ, El-Deiry WS. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res 2000; 6:335–46.
9. RD, El-Deiry WS. p53 –indipendent upregulation of KILLER /DR5 TRAIL receptor expression by glucocorticoids and interferon-γ. Exp Cell Res 2001; 262: 154–69.
<https://doi.org/10.1006/excr.2000.5073>
10. DW. From bench to clinic with apoptosis-based therapeutic agents. Nature 2000; 407:810–16.
<https://doi.org/10.1038/35037747>
11. Q, Liu B, Liu J, Cai R, Wang Y, Qian C. Synergistic inductionof tumor cell death by combining cisplatin with an oncolytic adenovirus carrying TRAIL. Mol Cell Biochem 2007; 304:315–23.
<https://doi.org/10.1007/s11010-007-9514-6>
12. T, Allen RL, Wyllie AH. Defying death after DNA damage. Nature 2000; 407:777–82.
<https://doi.org/10.1038/35037717>
13. M, Vavrova J, Vokurkova D, Tichy A, Knizek J, Psutka J. The importance of abrogation of G2-phase arrest in combined effect of TRAIL and ioniying radiation. Acta Bioch Pol 2005; 52:889–95.
14. A. The role of low-dose total body irradiation in treatment of non- Hodgkin’s lymphoma: a new look at an old method. Radiother Oncol 2000; 56:1–8.
<https://doi.org/10.1016/S0167-8140(00)00167-5>
15. JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A. Control of TRAIL –induced apoptosis by a family of signaling and decoy receptors. Science 1997; 277:818–21.
<https://doi.org/10.1126/science.277.5327.818>
16. S, El-Deiry WS. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 2003; 22:8628–33.
<https://doi.org/10.1038/sj.onc.1207232>
17. J, Ramadevi N, Nguyen D, Perkins C, Worthington E, Bhalla K. Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells. Blood 2000; 96:3900–6.
18. H, Takeda K, Hazakawa Y, Smith MJ, Okumura K. TRAIL and its receptor as targets for cancer therapy. Cancer Sci 2004; 95:777–83.
<https://doi.org/10.1111/j.1349-7006.2004.tb02181.x>
